Skip to main content
SpringerLink
Log in

Chronic Lymphocytic Leukemia

Diagnosis and Management

  • Chapter
Chronic Leukemias and Lymphomas

Part of the book series: Current Clinical Oncology ((CCO))

  • 154 Accesses

Abstract

CLL is characterized by the gradual accumulation of malignant lymphocytes in the bone marrow, blood, lymph nodes, liver, and spleen. Thus, the major clinical features are the sequelae of bone marrow failure and the compressive syndromes that result from gross enlargement of lymphoid organs. In addition, CLL is associated with humoral and cell-mediated immunodeficiencies as well as a greatly enhanced risk of autoimmune cytopenias—particularly autoimmune hemolytic anemia (AIHA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Calligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17: 399–408.

    Google Scholar 

  2. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11–18.

    PubMed  CAS  Google Scholar 

  3. Finch SC, Linet MS. Chronic Leukemias. Balliere’s Clin Haematol 1992; 5: 27.

    Article  CAS  Google Scholar 

  4. Finch SC, Finch CA. Summary of the studies at ABCC-RERF concerning the late hematological effects of atomic bomb exposure in Hiroshima and Nagasaki. RERF Technical Report. 1988; 23–88: 5.

    Google Scholar 

  5. Horwitz M. The genetics of familial leukemia. Leukemia 1997; 11: 1347–1359.

    Article  PubMed  CAS  Google Scholar 

  6. Yuille MR, Houlston RS, Catovsky D. Anticipation in familial chronic lymphocytic leukemia. Leukemia 1998; 12: 1696–1698.

    Article  PubMed  CAS  Google Scholar 

  7. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986; 39: 713–718.

    Article  PubMed  CAS  Google Scholar 

  8. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in in chronic lymphocytic leukemia: clinical, therapeutic and prognostic factors. Blood 2000; 95: 2786–2792.

    PubMed  CAS  Google Scholar 

  9. Kipps T, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475–2487.

    PubMed  CAS  Google Scholar 

  10. Giles FJ, O’Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter’s) transformation. Semin Oncol 1998; 25: 117–125.

    PubMed  CAS  Google Scholar 

  11. Bessudo A, Kipps TJ. Origin of high-grade lymphomas in Richter syndrome. Leuk Lymphoma 1995; 18: 367–372.

    Article  PubMed  CAS  Google Scholar 

  12. Momose H, Jaffe ES, Shin SS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin’ s disease. Mediation by Epstein-Barr virus. Am J Surg Pathol 1992; 16: 859–867.

    Article  PubMed  CAS  Google Scholar 

  13. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B-cells. Blood 1996; 87: 2615–2620.

    PubMed  CAS  Google Scholar 

  14. Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994; 15: 288–294.

    Article  PubMed  CAS  Google Scholar 

  15. Pritsch O, Maloum K, Dighiero G. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 1998; 25: 34–41.

    PubMed  CAS  Google Scholar 

  16. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of of chronic lymphocytic leukemia. Blood 1999; 94: 1948–1854.

    Google Scholar 

  17. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    PubMed  CAS  Google Scholar 

  18. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. NEngl JMed 1990; 323: 720–724.

    Article  CAS  Google Scholar 

  19. Juliusson G, Oscier DG, Gahrton G for the International Working Party on Chromosomes in Chronic Lymphocytic Leukemia. Second international compilation of data on 662 patients. Leuk Lymphoma 1991; 5 (Suppl): 21–25.

    Article  Google Scholar 

  20. Han T, Henderson ES, Emrich LJ, et al. Prognostic significance of karyotypic abnormalities in B-cell chronic lymphocytic leukemia: an update. Semin Hematol 1987; 24: 257–262.

    PubMed  CAS  Google Scholar 

  21. Bird ML, Ueshima Y, Rowley JD, et al. Chromosome abnormalities in B-cell chronic lymphocytic leukemia and their clinical correlations. Leukemia 1989; 3: 182–186.

    PubMed  CAS  Google Scholar 

  22. Dohner H, Stilenbauer S, Benner A, et al. Genonúc aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  PubMed  CAS  Google Scholar 

  23. Hanada M, Delia D, Aiello A, et al. Bc1–2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828.

    PubMed  CAS  Google Scholar 

  24. Konig A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bc1–2 in B-cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11: 258–265.

    Article  PubMed  CAS  Google Scholar 

  25. Aguilar-Santelises M, Rottenberg ME, Lewin N, et al. Bd-2, bax and p53 expression in B-cell chronic lymphocytic leukemia in relation to in vitro survival and clinical progression. Int J Cancer 1996; 69: 114–119.

    Article  PubMed  CAS  Google Scholar 

  26. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bc1–2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haematol 1996; 95: 513–517.

    Article  PubMed  CAS  Google Scholar 

  27. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246–250.

    PubMed  CAS  Google Scholar 

  28. Schaffner C, Stilgenbauer S, Rapplod GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748–753.

    PubMed  CAS  Google Scholar 

  29. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia. Lancet 1999; 353: 26–29.

    Article  PubMed  CAS  Google Scholar 

  30. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098–2104.

    Article  PubMed  CAS  Google Scholar 

  31. Staudt LM. Gene expression physiology and pathophysiology of the immune system. Trends in Immunology 2001; 22: 35–41.

    Article  PubMed  CAS  Google Scholar 

  32. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: report of the NCI-sponsored Working Group. Am J Hematol 1988; 29: 152–159.

    Article  PubMed  CAS  Google Scholar 

  33. Cheson BD, Bennett JM, Greyer M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    PubMed  CAS  Google Scholar 

  34. International Workshop on chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Ann Intern Med 1989;236:1989–1995.

    Google Scholar 

  35. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567–584.

    Article  PubMed  CAS  Google Scholar 

  36. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

    PubMed  CAS  Google Scholar 

  37. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645.

    PubMed  CAS  Google Scholar 

  38. Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Path 1997; 108: 278–282.

    Google Scholar 

  39. Criel A, Verhoef G, Vlietinck R, et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophentypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997; 97: 383–391.

    Article  PubMed  CAS  Google Scholar 

  40. Oscier DG, Matutes E, Copplestone A, et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 1997; 98: 934–939.

    Article  PubMed  CAS  Google Scholar 

  41. Lens D, Dyer MJ, Garcia-Marco JM, et al. P53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997; 99: 848–857.

    Article  PubMed  CAS  Google Scholar 

  42. Matutes E, and Catovsky S. The value of scoring systems for the diagnosis of biphenotypic leukaemia and mature B-cell disorders. Leukemia and Lymphoma 1994; 3 (Suppl. 1): 11–14.

    Article  Google Scholar 

  43. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.

    PubMed  CAS  Google Scholar 

  44. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic lymphocytic leukemia: recent progress and future directions. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol 59, Alan R. Liss, New York, 1987, p. 253.

    Google Scholar 

  45. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.

    Article  PubMed  CAS  Google Scholar 

  46. International Workshop on chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Ann Intern Med 1989;110:236–241.

    Google Scholar 

  47. Molica S, Brugiatelli M, Callea V, et al. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994; 52: 216–221.

    Article  PubMed  CAS  Google Scholar 

  48. Galton DAG. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94: 1005–1010.

    PubMed  CAS  Google Scholar 

  49. Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.

    Article  PubMed  CAS  Google Scholar 

  50. Montserrat E, Vinolas N, Rverer JC, et al. Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early stages. Nouv Rev Fr Hematol 1988; 30: 359–361.

    PubMed  CAS  Google Scholar 

  51. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histological pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis. Blood 1984; 64: 642–648.

    PubMed  CAS  Google Scholar 

  52. Desablens B, Claisse JF, Piprot-Choffat C, et al. Prognostic value of bone marrow biopsy in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1989; 31: 179–182.

    PubMed  CAS  Google Scholar 

  53. Molica S, Levato D, Dell’ Olio M, et al. Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis. Haematologica 1997; 82: 148–151.

    PubMed  CAS  Google Scholar 

  54. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in cell chronic lymphocytic leukemia, Br J Haematol 1996; 88: 4259–4264.

    CAS  Google Scholar 

  55. Keating M, Lerner S, Kantarjian H, et al. The serum beta2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 1995; 86 (Suppl 1): 606a.

    Google Scholar 

  56. Galton DAG, Wiltshaw E, Szur L, et al. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia Br J Haematol 1961; 7: 73–78.

    Article  PubMed  CAS  Google Scholar 

  57. Keating MJ. Chronic lymphocytic leukaemia. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia, 6th ed. WB Saunders Company, Philadelphia, 1996.

    Google Scholar 

  58. Han T, Ezdinli EZ, Emrich LJ, et al. Chlorambucil vs. chlorambucil-corticosteroid therapy in chronic lymphocytic leukaemia. Cancer 1973; 31: 502–507.

    Article  PubMed  CAS  Google Scholar 

  59. Catovsky D, Richards S, Fooks J, et al. CLL trials in the United Kingdom: The Medical Research Council CLL trials 1, 2 and 3. Leuk Lymphoma 1991; 5: 105–112.

    Article  Google Scholar 

  60. French Cooperative Group on Chronic Lymphocytic Leukaemia: effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukaemia (stage A): results of a randomised clinical trial in 612 patients. Blood 1990;75:1414–1420.

    Google Scholar 

  61. French Cooperative Group on Chronic Lymphocytic Leukaemia• chlorambucil in indolent chronic lymphocytic leukaemia. N Engl J Med 1998; 338: 1506–1514.

    Article  Google Scholar 

  62. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukaemia in advanced stages. Cancer 1985; 56: 2369–2371.

    Article  PubMed  CAS  Google Scholar 

  63. French Cooperative Group on Chronic Lymphocytic Leukaemia: a randomised trial of chlorambucil versus COP in stage B chronic lymphocytic leukaemia. Blood 1990;75:1422–1427.

    Google Scholar 

  64. Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine and prednisone as initial treatment for chronic lymphocytic leukaemia: long-term follow-up of an Eastern Cooperative Oncology Group randomised clinical trial. J Clin Oncol 1991; 9: 770–776.

    PubMed  CAS  Google Scholar 

  65. French Cooperative Group on Chronic Lymphocytic Leukaemia: long-term results of the CHOP regimen in Stage C chronic lymphocytic leukaemia. BrJHaematol 1989;73:334–339.

    Google Scholar 

  66. Hansen MM, Anderson E, Birgens H, et al. CHOP vs chlorambucil and prednisone in chronic lymphocytic leukaemia. Leuk Lymphoma 1991; 5: 97–103.

    Article  Google Scholar 

  67. Kimby E, Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukaemias of B-cell type. A randomised trial. Leuk Lymphoma 1991; 5: 93–97.

    Article  Google Scholar 

  68. CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukaemia: a meta-analysis of the randomised trials. J Natl Cancer Inst 1999; 91: 861–868.

    Article  Google Scholar 

  69. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukaemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700.

    PubMed  Google Scholar 

  70. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine-a new agent with major activity against chronic lymphocytic leukaemia. Blood 1989; 74: 19–25.

    PubMed  CAS  Google Scholar 

  71. Keating MJ, Kantarjian H, O’Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukaemia. J Clin Oncol 1991; 9: 44–49.

    PubMed  CAS  Google Scholar 

  72. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with low-grade non-Hodgkin’ s lymphoma and B-cell chronic lymphocytic leukaemia. J Clin Oncol 1999; 17: 1574–1579.

    PubMed  CAS  Google Scholar 

  73. Astrow AB. Fludarabine in chronic leukaemia. Lancet 1996; 347: 1420–1421.

    Article  PubMed  CAS  Google Scholar 

  74. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    Article  PubMed  CAS  Google Scholar 

  75. The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432–1438.

    Google Scholar 

  76. Leporrier M, Chevret S, Cazin B, et al. Randomised clinical trial comparing two anthracyclene-containing regimens (CHOP and CAP) and fludarabine in advanced chronic lymphocytic leukaemia. Blood 1999; 94 (Suppl 1): 603a.

    Google Scholar 

  77. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med 2000; 343: 1750–1757.

    Article  PubMed  CAS  Google Scholar 

  78. Koehl U, Li L, Nowak B, et al. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc Am Assoc Cancer Res 1997; 38: 2.

    Google Scholar 

  79. Bellosillo B, Villamor N, Colomer, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukaemia. Blood 1999; 94: 2836–2843.

    PubMed  CAS  Google Scholar 

  80. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75.

    PubMed  CAS  Google Scholar 

  81. O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination in chronic lymphocytic leukaemia. J Clin Oncol 2001; 19: 1414–1420.

    PubMed  Google Scholar 

  82. Byrd JC, Waselenko JK, Keating M, et al. Novel therapies for chronic lymphocytic leukaemia in the 21st century. Semin Oncol 2000; 27: 587–597.

    PubMed  CAS  Google Scholar 

  83. Nguyen DT, Amess J, Doughty H, et al. IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response in 48 patients. Eur J Haematol 1999; 62: 76–82.

    Article  PubMed  CAS  Google Scholar 

  84. O’Brien S, Kantarjian H, Thomas DA, et al. Rituximab dose escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170.

    PubMed  Google Scholar 

  85. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164.

    PubMed  CAS  Google Scholar 

  86. Osterborg A, Dyer M, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. J Clin Oncol 1997; 15: 1567–1574.

    PubMed  CAS  Google Scholar 

  87. Keating MJ, Byrd JC, Rai KR, et al. Mulicenter study of Campath-1 H in patients with chronic lymphocytic leukaemia refractory to fludarabine. Blood 1999; 94 (Suppl 1): 705a.

    Google Scholar 

  88. Kennedy B, Rawstron A, Richards S, Hillmen P. Campath-1H in CLL: immune reconstitution and viral infections during and after therapy. Blood 2000; 96 (Suppl 1): 164a.

    Google Scholar 

  89. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

    PubMed  CAS  Google Scholar 

  90. Rabinowe SN, Soiffier RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376.

    PubMed  CAS  Google Scholar 

  91. Dreger P, van Biezen A, Brand R, et al for the Chronic Leukaemia Working Party, EBMT. Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukaemia (CLL): the EBMT experience. Blood 2000; 96 (Suppl 1): 482a.

    Google Scholar 

  92. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311–315.

    PubMed  CAS  Google Scholar 

  93. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B-cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717–722.

    Article  PubMed  CAS  Google Scholar 

  94. Champlin R. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29.

    Article  PubMed  CAS  Google Scholar 

  95. Rondon G, Giralt S, Huh Y, et al. Graft-versus-leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukaemia. Bone Marrow Transplant 1996; 18: 669–672.

    PubMed  CAS  Google Scholar 

  96. Mehta J, Powles R, Kulkarni S, et al. Induction of graft-versus-host disease as immunotherapy of leukaemia relapsing after allogeneic transplantation: a single-center experience of 32 adults. Bone Marrow Transplant 1997; 20: 129–135.

    Article  PubMed  CAS  Google Scholar 

  97. deMagalhaes M, Donnenberg A, Hammed L et al. Induction of graft-vs-leukemia in apatient with chronic lymphocytic leukaemia. Bone Marrow Transplant 1997; 20: 175–177.

    Article  Google Scholar 

  98. Khouri IF, Munsell M, Yajzi S, et al. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): the case for early intervention. Blood 2000; 96 (Supp11): 205a.

    Google Scholar 

  99. Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991; 78: 1545–1551.

    PubMed  CAS  Google Scholar 

  100. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukemia: the importance of age, sex and response to treatment in survival. BrJHaematol 1989; 72: 141–149.

    Article  CAS  Google Scholar 

  101. Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94: 448–454.

    PubMed  CAS  Google Scholar 

  102. De Lima M, O’Brien S, Lerner S, Keating MJ. Chronic lymphocytic leukemia in the young patient. Semin Oncol 1998; 25: 107–116.

    PubMed  Google Scholar 

  103. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97.

    PubMed  CAS  Google Scholar 

  104. DiSanto JP, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM syndrome. Nature 1993; 361: 541–543.

    Article  PubMed  CAS  Google Scholar 

  105. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in and chronic lymphocytic leukemia. Nat Med 1997; 3: 984–989.

    Article  PubMed  CAS  Google Scholar 

  106. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924.

    PubMed  CAS  Google Scholar 

  107. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune disease. Blood 1993; 81: 2475–2800.

    PubMed  CAS  Google Scholar 

  108. Lewis FB, Schwartz RS, Damashek W. X-radiation and alkylating agents as possible `trigger’ mechanism in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol 1966; 1: 3–8.

    PubMed  CAS  Google Scholar 

  109. Byrd JC, Weiss RB, Kweeder SL, Diehl LF. Fludarabine therapy for lymphoid malignancies is associated with hemolytic anemia. Proc Am Soc Clin Oncol. 1994; 13: 304–309.

    Google Scholar 

  110. Weiss BR, Freiman, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885–1890.

    PubMed  CAS  Google Scholar 

  111. Mauro FR, Foa R, Cerretti R et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic and prognostic features. Blood 2000; 95: 2786–2792.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jamie D. Cavenagh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Andrew Lister MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA, USA

    Gary J. Schiller MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cavenagh, J.D., Lister, T.A. (2003). Chronic Lymphocytic Leukemia. In: Schiller, G.J. (eds) Chronic Leukemias and Lymphomas. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-308-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-308-8_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9732-8

  • Online ISBN: 978-1-59259-308-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation